Aligos TherapeuticsALGS -2.22%37 Debt-to-Equity is 0.14 as of Mar. 2026, which is 40% above its 10-year median of 0.10. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, Aligos Therapeutics ranks better than 53.89% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aligos Therapeutics's Debt-to-Equity or its related term are showing as below:
ALGS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.01 Med: 0.1 Max: 0.22
Current: 0.14
During the past 8 years, the highest Debt-to-Equity Ratio of Aligos Therapeutics was 0.22. The lowest was -1.01. And the median was 0.10.
ALGS's Debt-to-Equity is ranked better than 53.89% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ALGS: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Aligos Therapeutics Debt-to-Equity Related Terms
Aligos Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALGS vs SNTI, NTRB, CRVO: Debt-to-Equity Comparison
For the Biotechnology subindustry, Aligos Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (ALGS) has a Debt-to-Equity of 0.14 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aligos Therapeutics and its competitors. This is 40% above median its historical median of 0.10. According to the industry distribution chart, Aligos Therapeutics ranks #445 out of 965 companies in the Biotechnology industry, placing it in the top 46.1%.
Is Aligos Therapeutics' Debt-to-Equity too high?
Aligos Therapeutics' current Debt-to-Equity of 0.14 is 40% above median its 10-year median of 0.10. The Biotechnology industry median Debt-to-Equity is 0.16. Aligos Therapeutics' value of 0.14 is 12.5% below this industry median. Based on the distribution chart, Aligos Therapeutics ranks #445 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Debt-to-Equity compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #445 out of 965 companies for Debt-to-Equity. This puts Aligos Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Aligos Therapeutics' value of 0.14 is 12.5% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.16, Aligos Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current Debt-to-Equity of 0.14 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aligos Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current Debt-to-Equity is 0.14, which is 40% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current Debt-to-Equity is 0.14, which is 40% above median its 10-year median of 0.10 and 12.5% below the Biotechnology industry median of 0.16. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Debt-to-Equity is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for ALGS:
Debt-to-Equity: 0.14 (40% above median its 10-year median of 0.10)
GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
Industry Position: 12.5% below the Biotechnology median (#445 of 965)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score
Get the complete analysis for ALGS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
